BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3742966)

  • 1. [Collateral effects of anti-ulcer therapy with carbenoxolone. General considerations. A clinical case].
    Frabetti F; Zardi V; Grappa P; Dattola L; Bellodi G
    Clin Ter; 1986 Jun; 117(6):455-62. PubMed ID: 3742966
    [No Abstract]   [Full Text] [Related]  

  • 2. Side-effects of carbonoxolone.
    Baron JH
    Acta Gastroenterol Belg; 1983; 46(9-10):469-84. PubMed ID: 6673458
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hypokalemic myopathy secondary to carbenoxolone ulcer therapy (case report)].
    Corsi FM; Galgani S; Giacanelli M; Piazza G
    Riv Neurobiol; 1980; 26(3):350-6. PubMed ID: 7336082
    [No Abstract]   [Full Text] [Related]  

  • 4. Carbenoxolone and hypokalaemia.
    Metcalfe MJ; Entrican JH
    Lancet; 1987 Dec; 2(8574):1525-6. PubMed ID: 2892083
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for peptic ulcer.
    Jones FA; Hunt T
    World J Surg; 1979 Sep; 3(5):659-60. PubMed ID: 516781
    [No Abstract]   [Full Text] [Related]  

  • 6. Carbenoxolone and hypokalaemic hypertension: case report.
    Celi FS; D'Erasmo E; Oddo CM; Aliberti G
    Riv Eur Sci Med Farmacol; 1988 Nov; 10(5):383-4. PubMed ID: 3274721
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum carbenoxolone: ulcer-healing and metabolic effects.
    Wright PA; Reed PI; Davies WA; St John DJ; Young GP; House FR; Gribble RJ; Baron JH
    Scand J Gastroenterol Suppl; 1980; 65():41-8. PubMed ID: 6937940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of ulcer with acetoxolon].
    Gabor M
    Dtsch Med Wochenschr; 1985 Jun; 110(26):1057-8. PubMed ID: 4006763
    [No Abstract]   [Full Text] [Related]  

  • 9. [Controlled clinical evaluation of the therapeutic activity of 3 antiulcer agents in peptic ulcer: carbenoxolone, proglumide and zolimidine].
    Fossati C
    Clin Ter; 1979 Mar; 88(6):605-19. PubMed ID: 157245
    [No Abstract]   [Full Text] [Related]  

  • 10. Iatrogenic hypokalaemia.
    Haboubi NY; Barford AV; Asquith P
    Practitioner; 1985 Apr; 229(1402):302. PubMed ID: 2986090
    [No Abstract]   [Full Text] [Related]  

  • 11. [Undesirable effects of Biogastrone in the treatment of peptic ulcer (author's transl)].
    Zelenková J; Toman R; Svoboda M; Svihovec J
    Cesk Gastroenterol Vyz; 1976 Oct; 30(7):427-33. PubMed ID: 797473
    [No Abstract]   [Full Text] [Related]  

  • 12. [Double-blind study of proglumide, zolimidine and carbenoxolone in peptic ulcer and gastroduodenitis].
    Corazza GR; D'Ambro A; Grimoldi D
    Minerva Dietol Gastroenterol; 1979; 25(1):47-58. PubMed ID: 156316
    [No Abstract]   [Full Text] [Related]  

  • 13. [Life-threatening hypokalemic paralysis in carbenoxolone therapy].
    Thorwirth V; Oberdalhoff HE; Ritter G
    Nervenarzt; 1975 Jun; 46(6):322-4. PubMed ID: 1196451
    [No Abstract]   [Full Text] [Related]  

  • 14. [Controlled clinical study of the effectiveness of a new anti-ulcer drug: thiopropamine].
    Masoero G
    Clin Ter; 1979 Aug; 90(3):261-72. PubMed ID: 399873
    [No Abstract]   [Full Text] [Related]  

  • 15. Carbenoxolone sodium for gastric ulcer.
    Med Lett Drugs Ther; 1975 Aug; 17(16):67-8. PubMed ID: 1097883
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of peptic ulcer with cytoprotective substances].
    Fortunat W
    Wien Med Wochenschr; 1983; 133(4-5):94-8. PubMed ID: 6407215
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term therapy with carbenoxolone in the prevention of recurrence of gastric ulcer. Natural history and evolution of important side-effects and measures to avoid them.
    Ganguli PC; Mohamed SD
    Scand J Gastroenterol Suppl; 1980; 65():63-71. PubMed ID: 6937941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tolerance of carbenoxolone sodium in elderly patients (author's transl)].
    Hagenmüller F; Wurbs D; Classen M
    Leber Magen Darm; 1977 Dec; 7(6):385-8. PubMed ID: 593029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathogenesis of pseudohyperaldosteronism from carbenoxolone.
    Armanini D; Scali M; Zennaro MC; Karbowiak I; Wallace C; Lewicka S; Vecsei P; Mantero F
    J Endocrinol Invest; 1989 May; 12(5):337-41. PubMed ID: 2671110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoprotective therapy of gastric ulcers: a controlled clinical evaluation of triletide versus carbenoxolone.
    Campisi D; Cataldo MG; Paterna S; Bivona A; Barbarino C
    Pharmatherapeutica; 1985; 4(3 Spec No):166-70. PubMed ID: 3903785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.